Drugs / TAKC-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05018533 | Aug → Dec 2021 | — | TAK-Circulator Co. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAKC-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05018533 ↗ |
| Action | Inhibit | “inhibits the MEX3B synthesis” NCT05018533 ↗ |
| Modality | Antisense oligonucleotide | “TAKC-02 is a nucleic acid medicine, antisense oligonucleotide” NCT05018533 ↗ |
| Route | Inhaled | “multiple inhaled doses of TAKC-02” NCT05018533 ↗ |
| Target | MEX3B | “inhibits the MEX3B synthesis” NCT05018533 ↗ |